Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pneumococcal polysaccharide conjugate vaccine (adsorbed)
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Synflorix** is GSK's marketed 10-valent pneumococcal polysaccharide conjugate vaccine. It contains capsular polysaccharides from *Streptococcus pneumoniae* serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F, conjugated to carrier proteins and adsorbed to aluminium phosphate. The vaccine induces serotype-specific anti-capsular antibodies, including opsonophagocytic antibodies, to prevent invasive pneumococcal disease, pneumococcal pneumonia, and acute otitis media in infants and young children. It is supplied as an intramuscular suspension for injection and is used in age-appropriate primary-series and booster schedules. ([ema.europa.eu](https://www.ema.europa.eu/en/documents/product-information/synflorix-epar-product-information_en.pdf))
- Brand names
- Synflorix
- Other names
- 10-valent pneumococcal polysaccharide and non-typeable Haemophilus influenzae protein D conjugate vaccine10PnPCV-10 GSKPCV10 GSKPCV 10 GSKpneumococcal polysaccharide conjugate vaccine (adsorbed)
02
Targets
PD (Protein D)CPS (Streptococcus pneumoniae capsular polysaccharide)TT (Tetanus toxoid)
Beyond the preview
Go deeper on pneumococcal polysaccharide conjugate vaccine (adsorbed).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pneumococcal polysaccharide conjugate vaccine (adsorbed).